BPC-157 vs Semax
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BPC-157
Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.
Full details →Semax
Semax is a synthetic peptide derived from ACTH (adrenocorticotropic hormone). Developed in Russia as a nootropic and neuroprotective agent.
Full details →Side-by-Side Comparison
| Aspect | BPC-157 | Semax |
|---|---|---|
| Dose Range | 250 mcg–500 mcg | 300 mcg–600 mcg |
| Frequency | 2x daily | 2x daily |
| Cycle Length | 4–6 weeks | 2–4 weeks |
| Route | subcutaneous | intranasal |
| Mechanism | BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels. | Enhances BDNF expression, modulates dopamine and serotonin systems, and provides neuroprotective effects. Increases attention, memory formation, and learning. |
| Typical Dosage | Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied. | Intranasal: 200-600mcg 2-3 times daily. Higher doses (up to 1mg) used in clinical settings for stroke recovery. |
| Administration | Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable. | Primarily administered intranasally. N-Acetyl Semax Amidate (NASA) is a modified version with enhanced stability and potency. |
| Side Effects | Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses. | Generally well-tolerated. May cause mild irritability or hair shedding in some users. |
| Best For |
Key Differences
Unique to BPC-157:
Unique to Semax:
Key Studies
BPC-157
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
Current reviews in musculoskeletal medicine, 2025
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.
Alternative therapies in health and medicine, 2024
Semax
- Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.
British journal of pharmacology, 2025
- The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.
Acta naturae, 2025
- The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons.
Bulletin of experimental biology and medicine, 2025
Ready to Learn More?
Looking for trusted sources?